Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis.
Izanne RoosSifat SharminCharles MalpasSerkan OzakbasJeannette Lechner-ScottSuzanne HodgkinsonRaed AlroughaniSara EichauCavit BozAnneke Van Der WaltHelmut ButzkuevenKatherine BuzzardOlga SkibinaMatteo FoschiFrancois Grand'MaisonNevin A JohnPierre GrammondMurat TerziJulie PrévostMichael Harry BarnettGuy LaureysLiesbeth Van HijfteJose Luis Sanchez-MenoyoYolanda BlancoJiwon OhPamela McCombeCristina Ramo TelloAysun SoysalAlexandre PratPierre DuquetteBassem I YamoutSamia KhouryVincent van PeschRichard MacdonellMaria José SáMark SleeJens KuhleDavide MaimoneDaniele LA SpitaleriBarbara WillekensAbdallah Al AsmiEmma Clare TallantyreNeil P RobertsonAlasdair ColesJames William L BrownTomas KalincikPublished in: Multiple sclerosis (Houndmills, Basingstoke, England) (2024)
Cladribine is an effective therapy that can be viewed as a step up in effectiveness from fingolimod, but is less effective than the most potent intravenous MS therapies.